Avillion 
Welcome,         Profile    Billing    Logout  
  Products    Diseases   Products    Trials    News 
28 Trials

   

 
Trial + Data / EventsStatusPhNRegionInterventionsSponsorConditionsPrimary complStudy compl
sonelokimab (M1095) / Avillion, MoonLake Immunotherap
M1095-HS-302, NCT06411379: Study to Evaluate the Efficacy and Safety of Subcutaneous Sonelokimab Compared With Placebo in Adult Participants With Moderate to Severe Hidradenitis Suppurativa

Active, not recruiting
3
418
Europe, Canada, US, RoW
Sonelokimab, Placebo
MoonLake Immunotherapeutics AG
Hidradenitis Suppurativa
06/25
06/26
M1095-HS-301, NCT06411899: A Study to Evaluate the Efficacy and Safety of Subcutaneous Sonelokimab Compared With Placebo in Adult Participants With Moderate to Severe Hidradenitis Suppurativa

Active, not recruiting
3
422
Europe, Canada, US
Sonelokimab, Placebo
MoonLake Immunotherapeutics AG
Hidradenitis Suppurativa
06/25
06/26
IZAR-2, NCT06641089: Evaluation of Sonelokimab in Patients with Active Psoriatic Arthritis and Anti-TNFα Inadequate Response

Recruiting
3
600
US
Sonelokimab, Placebo, Risankizumab
MoonLake Immunotherapeutics AG
Arthritis, Psoriatic
01/27
01/27
IZAR-1, NCT06641076: Evaluation of Sonelokimab in Patients With Active Psoriatic Arthritis Naive to Biologic Disease-Modifying Antirheumatic Drug

Recruiting
3
960
US
Sonelokimab, Placebo
MoonLake Immunotherapeutics AG
Arthritis, Psoriatic
01/27
01/27
VELA-TEEN, NCT06768671: An Open-label, Single-arm Study to Evaluate Pharmacokinetics and Safety of Subcutaneous Sonelokimab in Adolescents With Moderate to Severe Hidradenitis Suppurativa

Recruiting
3
35
US
Sonelokimab
MoonLake Immunotherapeutics AG
Hidradenitis Suppurativa
03/26
03/26
NCT07007637: A Study to Evaluate the Long-term Safety, Tolerability, and Efficacy of Subcutaneous Sonelokimab in Participants With Moderate to Severe Hidradenitis Suppurativa

Enrolling by invitation
3
835
US
Sonelokimab
MoonLake Immunotherapeutics AG
Hidradenitis Suppurativa
06/28
06/28
2021-005947-58: Evaluation of Sonelokimab in Patients with Active Psoriatic Arthritis Zhodnocení přípravku sonelokimab u pacientů s aktivní psoriatickou artritidou

Not yet recruiting
2
200
RoW, Europe
Sonelokimab, adalimumab, Solution for injection in pre-filled syringe, Humira®
MoonLake Immunotherapeutics AG, MoonLake Immunotherapeutics AG
Active Psoriatic Arthritis, Chronic, inflammatory disease of the joints and the places where tendons and ligaments connect to bone., Diseases [C] - Musculoskeletal Diseases [C05]
 
 
M1095-HS-201, NCT05322473 / 2021-005928-38: Evaluation of Sonelokimab for the Treatment of Patients With Active Moderate to Severe Hidradenitis Suppurativa

Completed
2
234
Europe, Canada, US
Sonelokimab (M1095), Adalimumab, Placebo
MoonLake Immunotherapeutics AG, MoonLake Immunotherapeutics AG
Hidradenitis Suppurativa
05/23
08/23
2021-005928-38: Evaluation of Sonelokimab for the treatment of patients with active moderate to severe HS

Not yet recruiting
2
210
Europe, RoW
Sonelokimab, adalimumab, Solution for injection in pre-filled syringe, Humira®
MoonLake Immunotherapeutics AG, MoonLake Immunotherapeutics AG
Active moderate to severe hidradenitis suppurativa, Pain due to a skin condition that causes small, painful lumps to form under the skin and scarring on the skin., Diseases [C] - Skin and Connective Tissue Diseases [C17]
 
 
NCT05640245 / 2021-005947-58: Evaluation of Sonelokimab for the Treatment of Patients With Active Psoriatic Arthritis

Completed
2
207
Europe, US, RoW
Sonelokimab, M1095, Placebo, Adalimumab
MoonLake Immunotherapeutics AG, MoonLake Immunotherapeutics AG
Arthritis, Psoriatic
09/23
01/24
NCT06994936: An Open-label Study in Healthy Adults to Evaluate the Relative Bioequivalence of a Single-dose Administration of Sonelokimab Either by a Prefilled Syringe or an Autoinjector

Recruiting
1
120
Europe
Sonelokimab
MoonLake Immunotherapeutics AG
Relative Bioequivalence
10/25
10/25
Airsupra (budesonide/salbutamol) / AstraZeneca, Avillion
ANCHOR, NCT06422689: Combination Short-Acting BroNchodilator and Inhaled Corticosteroid Rescue Therapy on Health Outcomes in Routine Care

Recruiting
4
2000
US
Albuterol and budesonide inhalation aerosol, PT027
AstraZeneca, Premier HealthCare Solutions Inc.
Asthma
04/26
04/26
NCT06158893: Comparison of Preoperative Inhaled Budesonide With Salbutamol on the Respiratory Adverse Effects in Children Undergoing Tonsillectomy

Not yet recruiting
4
87
NA
Salbutamol, Budesonide, Saline
Assiut University
Preoperative Inhalation of Budesonide and Salbutamol in Children Undergoing Tonsillectomy
08/25
10/25
DARWIN, NCT06563102: Study to Investigate Changes in Airway Inflammation, Symptoms, and Rescue Therapy Utilization With AIRSUPRA Compared to Albuterol as Needed in Adults With Mild Asthma

Recruiting
4
100
US
Albuterol/Budesonide, AIRSUPRA, BDA MDI HFA, Albuterol, AS MDI
AstraZeneca, Fortrea
Mild Asthma
11/25
11/25
2018-003674-27: A clinical trial to evaluate the efficacy and safety of PT027 compared to PT007, PT008 and placebo in asthma patients 4 years of age or older (DENALI).

Not yet recruiting
3
1000
Europe, RoW
Budesonide/Albuterol Sulfate Pressurized Inhalation Suspension (BDA MDI), Albuterol Sulfate Pressurized Inhalation Suspension (AS MDI), Budesonide Pressurized Inhalation Suspension (BD MDI), PT027, PT007, PT008, Pressurised inhalation, suspension
Bond Avillion 2 Development LP, Bond Avillion 2 Development LP
Symptomatic Asthma, Symptomatic Asthma, Diseases [C] - Respiratory Tract Diseases [C08]
 
 
2018-003673-10: A clinical trial to evaluate the efficacy and safety of PT027 compared to PT007 in asthma patients 4 years of age or older (MANDALA).

Not yet recruiting
3
3100
Europe, RoW
Budesonide/Albuterol Sulfate Pressurized Inhalation Suspension (BDA MDI), Albuterol Sulfate Pressurized Inhalation Suspension (AS MDI), PT027, PT007, Pressurised inhalation, suspension, Ventolin Evohaler® 100 micrograms
Bond Avillion 2 Development LP, Bond Avillion 2 Development LP
Moderate to severe asthma, Asthma, Diseases [C] - Respiratory Tract Diseases [C08]
 
 
BREATH, NCT06245551: A Study to Investigate the Effects of PT027 (Budesonide/Albuterol Sulfate) Metered-dose Inhaler Compared With Placebo on Exercise-Induced Bronchoconstriction in Adult Patients With Asthma

Completed
3
64
RoW
Budesonide/albuterol metered-dose inhaler 160/180 μg, PT027 (BDA MDI) 160/180 μg, Placebo metered-dose inhaler, Placebo MDI
AstraZeneca
Asthma, Exercise-Induced
06/24
06/24
NCT05555290: PT027 Compared to PT007 in Patients With Asthma With Mannitol-induced Acute Airway Obstruction

Completed
3
21
US
PT027, PT007
AstraZeneca
Asthma
11/24
11/24
NCT05505734: A Comparison of PT027 vs PT007 Used as Needed in Participants With Asthma

Completed
3
2517
US
BDA MDI, AS MDI
Bond Avillion 2 Development LP, Parexel
Asthma
08/24
08/24
ACADIA, NCT06307665: Evaluating the Efficacy and Safety of PT027 Compared With PT007 Administered As Needed in Participants 12 to < 18 Years of Age With Asthma

Recruiting
3
440
US, RoW
BDA MDI, PT027, AS MDI, PT007
AstraZeneca, Parexel
Asthma
10/27
10/27
AIRSA001, NCT06429475: Anti-Inflammatory Reliever South Africa

Enrolling by invitation
3
1038
RoW
Budesonide/formoterol, No other intervention names, standard of care, beclomethasone or budesonide & salbutamol or mentelukast
University of KwaZulu
Asthma
05/25
05/26
BAIYUN, NCT06471257: A Study to Investigate Efficacy and Safety of PT027 Compared With PT007 in Symptomatic Chinese Adults With Asthma

Recruiting
3
790
RoW
Budesonide/Albuterol metered dose inhaler, MDI, PT027, Albuterol sulfate metered dose inhaler, MDI, PT007
AstraZeneca
Asthma
10/26
10/26
NCT06502366: A Study to Investigate the Effect on Lung Function of BDA Formulated With a New Propellant (HFO) Compared With an Approved Asthma Treatment (BDA With HFA Propellant) in Participants With Asthma

Recruiting
3
398
Europe, US, RoW
BDA MDI HFO 160/180 μg, BDA MDI HFA 160/180 μg, Placebo MDI HFA
AstraZeneca
Asthma
03/26
03/26
ARRIVAL, NCT06473779: Open-label Study to Assess Reduction of Background Asthma Medication While Sustaining Asthma Control and Clinical Remission With Tezepelumab in Patients 12-80yrs With Severe Asthma.

Recruiting
3
300
Europe, Canada, US, RoW
Tezepelumab, TEZSPIRE®, Budesonide/formoterol, SYMBICORT® pMDI, Albuterol/budesonide (AIRSUPRA®), AIRSUPRA®, Mannitol, ARIDOL®, Salbutamol, Sabumalin, albuterol, ventolin HFA, Proair HFA, Proventil HFA
AstraZeneca, Fortrea
Severe Asthma
06/27
06/27
ChiCTR2400085445: A Randomized, Double-blind, Multicentre, Event-driven, Parallel group, Phase III Study Evaluating the Efficacy and Safety of PT027 Compared with PT007 Administered As Needed in Symptomatic Chinese Adults with Asthma (BAIYUN)

Not yet recruiting
3
790
 
BDA MDI 160/180 μg (administered as 2 actuations of BDA MDI 80/90 μg) as needed; AS MDI 180 μg (administered as 2 actuations of AS MDI 90 μg) as needed
West China Hospital of Sichuan University; AstraZeneca Global R&D (China) Co.,LTD, Secondary sponsor:AstraZeneca Global R&D(China) Co.,LTD
Asthma
 
 
NCT06139991: Study to Assess the Pharmacokinetic Bioequivalence of Budesonide and Albuterol With an Alternate Propellant Compared to Current Propellant.

Completed
1
66
US
Treatment A (BDA MDI HFO), Treatment B (BDA MDI HFA)
AstraZeneca
Heathy Participants
05/24
05/24
PUTUO, NCT06514157: Phase I PK Study of Budesonide/Albuterol Delivered From PT027 in Healthy Chinese Participants.

Completed
1
14
RoW
budesonide/albuterol sulfate metered dose inhaleor (BDA MDI)
AstraZeneca
Healthy Volunteer
09/24
09/24
ChiCTR2200059926: Effects of combined use of salbutamol/budesonide in thoracic surgery on postoperative myocardial injury (MINS) – A prospective randomized clinical trial

Completed
N/A
304
 
None ;Salbutamol/budesonide
Affiliated Hospital of Xuzhou Medical University; Affiliated Hospital of Xuzhou Medical University, tutor provide
postoperative myocardial injury
 
 
Trial + Data / EventsStatusPhNRegionInterventionsSponsorConditionsPrimary complStudy compl
sonelokimab (M1095) / Avillion, MoonLake Immunotherap
M1095-HS-302, NCT06411379: Study to Evaluate the Efficacy and Safety of Subcutaneous Sonelokimab Compared With Placebo in Adult Participants With Moderate to Severe Hidradenitis Suppurativa

Active, not recruiting
3
418
Europe, Canada, US, RoW
Sonelokimab, Placebo
MoonLake Immunotherapeutics AG
Hidradenitis Suppurativa
06/25
06/26
M1095-HS-301, NCT06411899: A Study to Evaluate the Efficacy and Safety of Subcutaneous Sonelokimab Compared With Placebo in Adult Participants With Moderate to Severe Hidradenitis Suppurativa

Active, not recruiting
3
422
Europe, Canada, US
Sonelokimab, Placebo
MoonLake Immunotherapeutics AG
Hidradenitis Suppurativa
06/25
06/26
IZAR-2, NCT06641089: Evaluation of Sonelokimab in Patients with Active Psoriatic Arthritis and Anti-TNFα Inadequate Response

Recruiting
3
600
US
Sonelokimab, Placebo, Risankizumab
MoonLake Immunotherapeutics AG
Arthritis, Psoriatic
01/27
01/27
IZAR-1, NCT06641076: Evaluation of Sonelokimab in Patients With Active Psoriatic Arthritis Naive to Biologic Disease-Modifying Antirheumatic Drug

Recruiting
3
960
US
Sonelokimab, Placebo
MoonLake Immunotherapeutics AG
Arthritis, Psoriatic
01/27
01/27
VELA-TEEN, NCT06768671: An Open-label, Single-arm Study to Evaluate Pharmacokinetics and Safety of Subcutaneous Sonelokimab in Adolescents With Moderate to Severe Hidradenitis Suppurativa

Recruiting
3
35
US
Sonelokimab
MoonLake Immunotherapeutics AG
Hidradenitis Suppurativa
03/26
03/26
NCT07007637: A Study to Evaluate the Long-term Safety, Tolerability, and Efficacy of Subcutaneous Sonelokimab in Participants With Moderate to Severe Hidradenitis Suppurativa

Enrolling by invitation
3
835
US
Sonelokimab
MoonLake Immunotherapeutics AG
Hidradenitis Suppurativa
06/28
06/28
2021-005947-58: Evaluation of Sonelokimab in Patients with Active Psoriatic Arthritis Zhodnocení přípravku sonelokimab u pacientů s aktivní psoriatickou artritidou

Not yet recruiting
2
200
RoW, Europe
Sonelokimab, adalimumab, Solution for injection in pre-filled syringe, Humira®
MoonLake Immunotherapeutics AG, MoonLake Immunotherapeutics AG
Active Psoriatic Arthritis, Chronic, inflammatory disease of the joints and the places where tendons and ligaments connect to bone., Diseases [C] - Musculoskeletal Diseases [C05]
 
 
M1095-HS-201, NCT05322473 / 2021-005928-38: Evaluation of Sonelokimab for the Treatment of Patients With Active Moderate to Severe Hidradenitis Suppurativa

Completed
2
234
Europe, Canada, US
Sonelokimab (M1095), Adalimumab, Placebo
MoonLake Immunotherapeutics AG, MoonLake Immunotherapeutics AG
Hidradenitis Suppurativa
05/23
08/23
2021-005928-38: Evaluation of Sonelokimab for the treatment of patients with active moderate to severe HS

Not yet recruiting
2
210
Europe, RoW
Sonelokimab, adalimumab, Solution for injection in pre-filled syringe, Humira®
MoonLake Immunotherapeutics AG, MoonLake Immunotherapeutics AG
Active moderate to severe hidradenitis suppurativa, Pain due to a skin condition that causes small, painful lumps to form under the skin and scarring on the skin., Diseases [C] - Skin and Connective Tissue Diseases [C17]
 
 
NCT05640245 / 2021-005947-58: Evaluation of Sonelokimab for the Treatment of Patients With Active Psoriatic Arthritis

Completed
2
207
Europe, US, RoW
Sonelokimab, M1095, Placebo, Adalimumab
MoonLake Immunotherapeutics AG, MoonLake Immunotherapeutics AG
Arthritis, Psoriatic
09/23
01/24
NCT06994936: An Open-label Study in Healthy Adults to Evaluate the Relative Bioequivalence of a Single-dose Administration of Sonelokimab Either by a Prefilled Syringe or an Autoinjector

Recruiting
1
120
Europe
Sonelokimab
MoonLake Immunotherapeutics AG
Relative Bioequivalence
10/25
10/25
Airsupra (budesonide/salbutamol) / AstraZeneca, Avillion
ANCHOR, NCT06422689: Combination Short-Acting BroNchodilator and Inhaled Corticosteroid Rescue Therapy on Health Outcomes in Routine Care

Recruiting
4
2000
US
Albuterol and budesonide inhalation aerosol, PT027
AstraZeneca, Premier HealthCare Solutions Inc.
Asthma
04/26
04/26
NCT06158893: Comparison of Preoperative Inhaled Budesonide With Salbutamol on the Respiratory Adverse Effects in Children Undergoing Tonsillectomy

Not yet recruiting
4
87
NA
Salbutamol, Budesonide, Saline
Assiut University
Preoperative Inhalation of Budesonide and Salbutamol in Children Undergoing Tonsillectomy
08/25
10/25
DARWIN, NCT06563102: Study to Investigate Changes in Airway Inflammation, Symptoms, and Rescue Therapy Utilization With AIRSUPRA Compared to Albuterol as Needed in Adults With Mild Asthma

Recruiting
4
100
US
Albuterol/Budesonide, AIRSUPRA, BDA MDI HFA, Albuterol, AS MDI
AstraZeneca, Fortrea
Mild Asthma
11/25
11/25
2018-003674-27: A clinical trial to evaluate the efficacy and safety of PT027 compared to PT007, PT008 and placebo in asthma patients 4 years of age or older (DENALI).

Not yet recruiting
3
1000
Europe, RoW
Budesonide/Albuterol Sulfate Pressurized Inhalation Suspension (BDA MDI), Albuterol Sulfate Pressurized Inhalation Suspension (AS MDI), Budesonide Pressurized Inhalation Suspension (BD MDI), PT027, PT007, PT008, Pressurised inhalation, suspension
Bond Avillion 2 Development LP, Bond Avillion 2 Development LP
Symptomatic Asthma, Symptomatic Asthma, Diseases [C] - Respiratory Tract Diseases [C08]
 
 
2018-003673-10: A clinical trial to evaluate the efficacy and safety of PT027 compared to PT007 in asthma patients 4 years of age or older (MANDALA).

Not yet recruiting
3
3100
Europe, RoW
Budesonide/Albuterol Sulfate Pressurized Inhalation Suspension (BDA MDI), Albuterol Sulfate Pressurized Inhalation Suspension (AS MDI), PT027, PT007, Pressurised inhalation, suspension, Ventolin Evohaler® 100 micrograms
Bond Avillion 2 Development LP, Bond Avillion 2 Development LP
Moderate to severe asthma, Asthma, Diseases [C] - Respiratory Tract Diseases [C08]
 
 
BREATH, NCT06245551: A Study to Investigate the Effects of PT027 (Budesonide/Albuterol Sulfate) Metered-dose Inhaler Compared With Placebo on Exercise-Induced Bronchoconstriction in Adult Patients With Asthma

Completed
3
64
RoW
Budesonide/albuterol metered-dose inhaler 160/180 μg, PT027 (BDA MDI) 160/180 μg, Placebo metered-dose inhaler, Placebo MDI
AstraZeneca
Asthma, Exercise-Induced
06/24
06/24
NCT05555290: PT027 Compared to PT007 in Patients With Asthma With Mannitol-induced Acute Airway Obstruction

Completed
3
21
US
PT027, PT007
AstraZeneca
Asthma
11/24
11/24
NCT05505734: A Comparison of PT027 vs PT007 Used as Needed in Participants With Asthma

Completed
3
2517
US
BDA MDI, AS MDI
Bond Avillion 2 Development LP, Parexel
Asthma
08/24
08/24
ACADIA, NCT06307665: Evaluating the Efficacy and Safety of PT027 Compared With PT007 Administered As Needed in Participants 12 to < 18 Years of Age With Asthma

Recruiting
3
440
US, RoW
BDA MDI, PT027, AS MDI, PT007
AstraZeneca, Parexel
Asthma
10/27
10/27
AIRSA001, NCT06429475: Anti-Inflammatory Reliever South Africa

Enrolling by invitation
3
1038
RoW
Budesonide/formoterol, No other intervention names, standard of care, beclomethasone or budesonide & salbutamol or mentelukast
University of KwaZulu
Asthma
05/25
05/26
BAIYUN, NCT06471257: A Study to Investigate Efficacy and Safety of PT027 Compared With PT007 in Symptomatic Chinese Adults With Asthma

Recruiting
3
790
RoW
Budesonide/Albuterol metered dose inhaler, MDI, PT027, Albuterol sulfate metered dose inhaler, MDI, PT007
AstraZeneca
Asthma
10/26
10/26
NCT06502366: A Study to Investigate the Effect on Lung Function of BDA Formulated With a New Propellant (HFO) Compared With an Approved Asthma Treatment (BDA With HFA Propellant) in Participants With Asthma

Recruiting
3
398
Europe, US, RoW
BDA MDI HFO 160/180 μg, BDA MDI HFA 160/180 μg, Placebo MDI HFA
AstraZeneca
Asthma
03/26
03/26
ARRIVAL, NCT06473779: Open-label Study to Assess Reduction of Background Asthma Medication While Sustaining Asthma Control and Clinical Remission With Tezepelumab in Patients 12-80yrs With Severe Asthma.

Recruiting
3
300
Europe, Canada, US, RoW
Tezepelumab, TEZSPIRE®, Budesonide/formoterol, SYMBICORT® pMDI, Albuterol/budesonide (AIRSUPRA®), AIRSUPRA®, Mannitol, ARIDOL®, Salbutamol, Sabumalin, albuterol, ventolin HFA, Proair HFA, Proventil HFA
AstraZeneca, Fortrea
Severe Asthma
06/27
06/27
ChiCTR2400085445: A Randomized, Double-blind, Multicentre, Event-driven, Parallel group, Phase III Study Evaluating the Efficacy and Safety of PT027 Compared with PT007 Administered As Needed in Symptomatic Chinese Adults with Asthma (BAIYUN)

Not yet recruiting
3
790
 
BDA MDI 160/180 μg (administered as 2 actuations of BDA MDI 80/90 μg) as needed; AS MDI 180 μg (administered as 2 actuations of AS MDI 90 μg) as needed
West China Hospital of Sichuan University; AstraZeneca Global R&D (China) Co.,LTD, Secondary sponsor:AstraZeneca Global R&D(China) Co.,LTD
Asthma
 
 
NCT06139991: Study to Assess the Pharmacokinetic Bioequivalence of Budesonide and Albuterol With an Alternate Propellant Compared to Current Propellant.

Completed
1
66
US
Treatment A (BDA MDI HFO), Treatment B (BDA MDI HFA)
AstraZeneca
Heathy Participants
05/24
05/24
PUTUO, NCT06514157: Phase I PK Study of Budesonide/Albuterol Delivered From PT027 in Healthy Chinese Participants.

Completed
1
14
RoW
budesonide/albuterol sulfate metered dose inhaleor (BDA MDI)
AstraZeneca
Healthy Volunteer
09/24
09/24
ChiCTR2200059926: Effects of combined use of salbutamol/budesonide in thoracic surgery on postoperative myocardial injury (MINS) – A prospective randomized clinical trial

Completed
N/A
304
 
None ;Salbutamol/budesonide
Affiliated Hospital of Xuzhou Medical University; Affiliated Hospital of Xuzhou Medical University, tutor provide
postoperative myocardial injury
 
 

Download Options